PMID- 10078088
OWN - NLM
STAT- MEDLINE
DCOM- 19990318
LR  - 20190503
IS  - 1355-6037 (Print)
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 79
IP  - 6
DP  - 1998 Jun
TI  - Quality of life in chronic heart failure: cilazapril and captopril versus 
      placebo. Cilazapril-Captopril Multicentre Group.
PG  - 593-8
AB  - OBJECTIVE: To measure quality of life (QOL) in patients with mild to moderate 
      heart failure treated with angiotensin converting enzyme (ACE) inhibitors 
      cilazapril or captopril. DESIGN: Randomised, double blind, placebo controlled, 
      parallel groups trial. SUBJECTS: 367 patients with New York Heart Association 
      (NYHA) heart failure class II (62%), III (36%) or IV (1%). METHODS: Patients were 
      randomised to receive cilazapril 1 mg daily (n = 191) or captopril 25 mg three 
      times daily (n = 90) for 24 weeks, or placebo for 12 weeks followed by cilazapril 
      1 mg daily for a further 12 weeks (n = 86). If patients had not responded after 
      four weeks cilazapril was increased to 2.5 mg daily and captopril to 50 mg three 
      times daily. QOL was assessed at baseline, 12, and 24 weeks using the sickness 
      impact profile (SIP), the profile of mood states (POMS), the Mahler index of 
      dyspnoea-fatigue, and a health status index (HSI). RESULTS: The physical 
      dimension of the SIP averaged 7 units at baseline and improved after 12 weeks by 
      2.24 units in the cilazapril group, 2.38 units in the captopril group, and 1.51 
      units in the placebo group. The difference between drug and placebo was therefore 
      0.73 units (95% CI -0.86 to 2.32) for cilazapril, and 0.87 units (95% CI -0.96 to 
      2.70) for captopril, with small non-significant effect sizes (a statistical 
      method for estimating the importance of a treatment related change) of 0.12 and 
      0.14. Similar results were observed for the total POMS and HSI scores. Although 
      QOL improved more on the ACE inhibitors than on placebo, the effect sizes were 
      not significant (< or = 0.26). CONCLUSIONS: Improvements in QOL in mild to 
      moderate heart failure were small when treated with cilazapril or captopril 
      compared with placebo.
FAU - Bulpitt, C J
AU  - Bulpitt CJ
AD  - Epidemiology Research Unit, Hammersmith Hospital, Imperial College of Medicine, 
      London, UK.
FAU - Fletcher, A E
AU  - Fletcher AE
FAU - Dossegger, L
AU  - Dossegger L
FAU - Neiss, A
AU  - Neiss A
FAU - Nielsen, T
AU  - Nielsen T
FAU - Viergutz, S
AU  - Viergutz S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 19KW7PI29F (Cilazapril)
RN  - 9G64RSX1XD (Captopril)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Captopril/*therapeutic use
MH  - Cilazapril/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Heart Failure/*drug therapy/psychology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - *Quality of Life
PMC - PMC1728718
EDAT- 1999/03/17 00:00
MHDA- 1999/03/17 00:01
PMCR- 2001/06/01
CRDT- 1999/03/17 00:00
PHST- 1999/03/17 00:00 [pubmed]
PHST- 1999/03/17 00:01 [medline]
PHST- 1999/03/17 00:00 [entrez]
PHST- 2001/06/01 00:00 [pmc-release]
AID - 10.1136/hrt.79.6.593 [doi]
PST - ppublish
SO  - Heart. 1998 Jun;79(6):593-8. doi: 10.1136/hrt.79.6.593.